GenSight Biologics
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye, and central nervous system. The last earnings update was 24 days ago. More info.
Add to Portfolio Compare Print
- GenSight Biologics has significant price volatility in the past 3 months.
SIGHT Share Price and Events
7 Day Returns
1 Year Returns
SIGHT Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| GenSight Biologics (SIGHT) | -13.1% | -24.4% | -24.6% | -50.9% | - | - |
| FR Biotechs | 0.4% | -3.2% | 1.1% | -34.4% | -52% | -36.4% |
| FR Market | 0.6% | -3.3% | 3.8% | -3.9% | 27.3% | 27.2% |
1 Year Return vs Industry and Market
- SIGHT underperformed the Biotechs industry which returned -34.4% over the past year.
- SIGHT underperformed the Market in France which returned -3.9% over the past year.
SIGHT Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for GenSight Biologics. This is due to cash flow or dividend data being unavailable. The share price is €1.516.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for GenSight Biologics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
GenSight Biologics's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in EUR | €-1.37 |
| ENXTPA:SIGHT Share Price ** | ENXTPA (2019-05-22) in EUR | €1.52 |
| France Biotechs Industry PE Ratio | Median Figure of 8 Publicly-Listed Biotechs Companies | 18.5x |
| France Market PE Ratio | Median Figure of 419 Publicly-Listed Companies | 17.44x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of GenSight Biologics.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = ENXTPA:SIGHT Share Price ÷ EPS (both in EUR) = 1.52 ÷ -1.37 |
-1.11x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- GenSight Biologics is loss making, we can't compare its value to the FR Biotechs industry average.
- GenSight Biologics is loss making, we can't compare the value of its earnings to the France market.
Price based on expected Growth
Does
GenSight Biologics's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -1.11x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts |
22.8%per year |
| France Biotechs Industry PEG Ratio | Median Figure of 7 Publicly-Listed Biotechs Companies | 0.34x |
| France Market PEG Ratio | Median Figure of 269 Publicly-Listed Companies | 1.47x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for GenSight Biologics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
GenSight Biologics's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in EUR | €0.97 |
| ENXTPA:SIGHT Share Price * | ENXTPA (2019-05-22) in EUR | €1.52 |
| France Biotechs Industry PB Ratio | Median Figure of 33 Publicly-Listed Biotechs Companies | 2.27x |
| France Market PB Ratio | Median Figure of 620 Publicly-Listed Companies | 1.44x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = ENXTPA:SIGHT Share Price ÷ Book Value per Share (both in EUR) = 1.52 ÷ 0.97 |
1.57x |
* Primary Listing of GenSight Biologics.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- GenSight Biologics is good value based on assets compared to the FR Biotechs industry average.
Value checks
We assess GenSight Biologics's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) GenSight Biologics has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
SIGHT Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare GenSight Biologics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
- Unable to compare GenSight Biologics's earnings growth to the France market average as it is expected to be loss making during the next 1-3 years.
- GenSight Biologics's revenue growth is expected to exceed the France market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| ENXTPA:SIGHT Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts | 22.8% |
| ENXTPA:SIGHT Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts | 82.8% |
| France Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 32.9% |
| France Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 39.7% |
| France Market Earnings Growth Rate | Market Cap Weighted Average | 13.3% |
| France Market Revenue Growth Rate | Market Cap Weighted Average | 4.9% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2020-12-31 | 24 | -19 | -22 | 1 |
| 2019-12-31 | 7 | -23 | -23 | 1 |
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 4 | -28 | -33 |
| 2018-09-30 | 4 | -25 | -30 |
| 2018-06-30 | 4 | -21 | -26 |
| 2018-03-31 | 4 | -20 | -25 |
| 2017-12-31 | 4 | -19 | -24 |
| 2017-09-30 | 3 | -19 | -23 |
| 2017-06-30 | 3 | -20 | -23 |
| 2017-03-31 | 3 | -20 | -22 |
| 2016-12-31 | 3 | -20 | -22 |
| 2016-09-30 | 3 | -18 | -20 |
| 2016-06-30 | 4 | -17 | -18 |
| 2016-03-31 | 4 | -15 | -16 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
All data from GenSight Biologics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2020-12-31 | -0.76 | -0.70 | -0.80 | 3.00 |
| 2019-12-31 | -0.80 | -0.80 | -0.80 | 1.00 |
| Date (Data in EUR Millions) | EPS * |
|---|---|
| 2018-12-31 | -1.37 |
| 2018-09-30 | -1.21 |
| 2018-06-30 | -1.06 |
| 2018-03-31 | -1.08 |
| 2017-12-31 | -1.10 |
| 2017-09-30 | -1.14 |
| 2017-06-30 | -1.18 |
| 2017-03-31 | -1.26 |
| 2016-12-31 | -1.36 |
| 2016-09-30 | -1.36 |
| 2016-06-30 | -1.35 |
| 2016-03-31 | -1.29 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if GenSight Biologics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess GenSight Biologics's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the France market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the France market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
GenSight Biologics has a total score of 2/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
SIGHT Past Performance
How has GenSight Biologics performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- GenSight Biologics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare GenSight Biologics's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare GenSight Biologics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from GenSight Biologics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 4.35 | -33.45 | 8.36 | 29.03 |
| 2018-09-30 | 4.04 | -29.56 | 8.39 | 24.78 |
| 2018-06-30 | 3.74 | -25.66 | 8.94 | 20.01 |
| 2018-03-31 | 3.72 | -24.88 | 9.23 | 19.09 |
| 2017-12-31 | 3.70 | -24.11 | 9.02 | 18.68 |
| 2017-09-30 | 3.41 | -23.50 | 8.95 | 17.84 |
| 2017-06-30 | 3.12 | -22.88 | 8.89 | 17.01 |
| 2017-03-31 | 3.06 | -22.48 | 8.00 | 17.46 |
| 2016-12-31 | 3.00 | -22.08 | 7.11 | 17.91 |
| 2016-09-30 | 3.32 | -20.21 | 6.27 | 15.83 |
| 2016-06-30 | 3.64 | -18.34 | 5.34 | 13.74 |
| 2016-03-31 | 3.60 | -15.99 | 4.78 | 11.92 |
| 2015-12-31 | 3.56 | -13.65 | 4.23 | 10.09 |
| 2015-09-30 | 2.88 | -11.26 | 3.33 | 9.33 |
| 2015-06-30 | 2.21 | -8.88 | 2.54 | 8.56 |
| 2015-03-31 | 1.65 | -7.77 | 2.15 | 7.33 |
| 2014-12-31 | 1.10 | -6.67 | 1.76 | 6.09 |
| 2013-12-31 | 0.91 | -2.76 | 1.05 | 2.69 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if GenSight Biologics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if GenSight Biologics has efficiently used its assets last year compared to the FR Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if GenSight Biologics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess GenSight Biologics's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
GenSight Biologics has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
SIGHT Health
How is GenSight Biologics's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up GenSight Biologics's finances.
The net worth of a company is the difference between its assets and liabilities.
- GenSight Biologics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- GenSight Biologics's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 10.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from GenSight Biologics Company Filings, last reported 4 months ago.
| Date (Data in EUR Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 23.87 | 3.44 | 26.24 |
| 2018-09-30 | 23.87 | 3.44 | 26.24 |
| 2018-06-30 | 44.64 | 3.41 | 41.68 |
| 2018-03-31 | 44.64 | 3.41 | 41.68 |
| 2017-12-31 | 55.00 | 3.03 | 55.45 |
| 2017-09-30 | 55.00 | 3.03 | 55.45 |
| 2017-06-30 | 66.27 | 2.70 | 63.62 |
| 2017-03-31 | 66.27 | 2.70 | 63.62 |
| 2016-12-31 | 53.34 | 2.92 | 53.98 |
| 2016-09-30 | 53.34 | 2.92 | 53.98 |
| 2016-06-30 | |||
| 2016-03-31 | 29.33 | 0.62 | 30.06 |
| 2015-12-31 | 29.33 | 0.62 | 30.06 |
| 2015-09-30 | 29.33 | 0.62 | 30.06 |
| 2015-06-30 | 6.04 | 0.64 | 6.00 |
| 2015-03-31 | 6.04 | 0.64 | 6.00 |
| 2014-12-31 | 10.58 | 0.63 | 12.07 |
| 2013-12-31 | 16.97 | 0.00 | 17.09 |
- GenSight Biologics's level of debt (14.4%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (0% vs 14.4% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- GenSight Biologics has less than a year of cash runway based on current free cash flow.
- GenSight Biologics has less than a year of cash runway if free cash flow continues to grow at historical rates of 18.1% each year.
Financial health checks
We assess GenSight Biologics's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) GenSight Biologics has a total score of 3/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
SIGHT Dividends
What is GenSight Biologics's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
€2,000 of
GenSight Biologics
shares you are expected to receive
€0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate GenSight Biologics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate GenSight Biologics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
| Europe Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 9 Stocks | 0.8% |
| France Market Average Dividend Yield | Market Cap Weighted Average of 323 Stocks | 3.1% |
| France Minimum Threshold Dividend Yield | 10th Percentile | 0.9% |
| France Bottom 25% Dividend Yield | 25th Percentile | 1.6% |
| France Top 25% Dividend Yield | 75th Percentile | 4.5% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in €) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2020-12-31 | 0.00 | 1.00 |
| 2019-12-31 | 0.00 | 1.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as GenSight Biologics has not reported any payouts.
- Unable to verify if GenSight Biologics's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess GenSight Biologics's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can GenSight Biologics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) GenSight Biologics has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
SIGHT Management
CEO
| COMPENSATION | €1,558,018 |
| AGE | 61 |
| TENURE AS CEO | 7.3 years |
CEO Bio
Dr. Bernard Gilly, Ph.D. serves as Chairman at iBionext. He serves as President and Chairman of the Board at ChronoLife SAS. He co-founded Fovea Pharmaceuticals, SA in 2005 and serves as its Chairman, Chief Executive Officer and President. Dr. Gilly Co-Founded GenSight Biologics SA in 2011 and serves as its Chief Executive Officer and served as its Executive Chairman. Dr. Gilly has been the President and General Manager of Fovea since November 2005. He serves as the Chief Executive Officer of GenSight Biologics SA. He has been the Executive Chairman of Pixium Vision SA since January 6, 2015 and was its Interim Chief Executive Officer since April 24, 2019 until May 13, 2019. He Co-Founded Gecko Biomedical SAS and serves as its Executive Chairman. In 2012, he founded the iBionext Network. He is a Director at GrAI Matter Labs. He served as Senior Vice President of the Ophthalmology Division of Sanofi until March 2012. He served as the President of TRANSGENE. He was a Venture Partner of Sofinnova Partners from December 2000 to October 2005 and joined in December 2000. He was a Partner at Sofinnova Partners from 2000 to 2005. He began his career as a Scientist at the Institut National de la Recherche Agronomique (INRA). He served as a Consultant of Food and Agriculture Organization of the United Nations and International Monetary Fund (IMF). He served as a Co-President and Vice President of Research and Development of Sanofi Pasteur SA and Vice President of Research and Development of bioMérieux SA. Dr. Gilly served as the Chief Executive Officer of TRANSGENE (Director General) from 1992 to January 2001. From 1994 to June 1997, he served as Research Director of BioMerieux. He served in various capacities at Pasteur Merieux, including Vice President of Research and Development from 1990 to 1994. He serves as the Chairman of the Board of Sofinnova Partners. He serves as Chairman of the Supervisory Board of Faust Pharmaceuticals SA. He serves as Director at GenSight Biologics SA. He serves as Member of the Board of Directors of Chronocam SAS, Brain Ever, Chrono Life, Tilak, Noxxon Pharma and ENS Lyon. He served as a Member of the Board of Directors of HighDeal S.A., CNRS, Ecole Normale Supérieure de Lyon and Institut National de la Santé et de la Recherche Médicale (INSERM). He served as the Chairman of the Board of WebSurg. He served as the Chairman of Eye Tech Care SA. He served as a Director of Sequoia Pharmaceuticals, Inc. He served as the Chairman at Enterome SA. until September 2015 and also served as its Non-Executive Director. He was a Director of Kala Pharmaceuticals, Inc. since November 27, 2012. He served as the Chairman of the Board of CareX S.A. and Domain Therapeutics S.A. He served as a Director of Domain Therapeutics S.A. He served as an Independent Director of Wavecom SA from April 1999 to March 6, 2009. Dr. Gilly is a graduate of Ecole Nationale d'Agronomie and has a Ph.D. in Biology and Bio-Economics from Université de Rennes I and University of Rhode-Island. He also has an MBA from INSEAD (France). He holds an AMP from INSEAD.
CEO Compensation
- Bernard's compensation has been consistent with company performance over the past year, both up more than 20%.
- Bernard's remuneration is higher than average for companies of similar size in France.
Management Team Tenure
Average tenure of the GenSight Biologics management team in years:
- The tenure for the GenSight Biologics management team is about average.
Management Team
Bernard Gilly
Co-Founder
€2M
61
7.3 yrs
José-Alain Sahel
Scientific Founder
Botond Roska
Scientific Founder & Chairman of Scientific Advisory Board
Jean Bennett
Scientific Founder & Vice Chairman of Scientific Advisory Board
Luk Vandenberghe
Scientific Founder & Member of Scientific Advisory Board
Serge Picaud
Scientific Founder & Member of Scientific Advisory Board
Connie Cepko
Scientific Founders & Member of Scientific Advisory Board
Thomas Gidoin
Chief Financial Officer
35
3.8 yrs
Julio Benedicto
Vice President of Marketing
1.3 yrs
Barrett Katz
Chief Medical Officer
1.6 yrs
Board of Directors Tenure
Average tenure and age of the GenSight Biologics board of directors in years:
- The tenure for the GenSight Biologics board of directors is about average.
Board of Directors
Mike Wyzga
Chairman of the Board
€170K
63
3.2 yrs
Bernard Gilly
Co-Founder
€2M
61
José-Alain Sahel
Scientific Founder
Botond Roska
Scientific Founder & Chairman of Scientific Advisory Board
Jean Bennett
Scientific Founder & Vice Chairman of Scientific Advisory Board
Luk Vandenberghe
Scientific Founder & Member of Scientific Advisory Board
7.1 yrs
Serge Picaud
Scientific Founder & Member of Scientific Advisory Board
7.1 yrs
Connie Cepko
Scientific Founders & Member of Scientific Advisory Board
7.1 yrs
Peter Goodfellow
Independent Director
€76K
67
Ernst Bamberg
Member of Scientific Advisory Board
7.1 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (€) | Value (€) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess GenSight Biologics's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) GenSight Biologics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
SIGHT News
Simply Wall St News
Investors Who Bought GenSight Biologics (EPA:SIGHT) Shares A Year Ago Are Now Down 64%
Given that GenSight Biologics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth. … In the last year GenSight Biologics saw its revenue grow by 20%.
Simply Wall St - – Full articleDo Institutions Own GenSight Biologics S.A. (EPA:SIGHT) Shares?
A look at the shareholders of GenSight Biologics S.A. … Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … With a market capitalization of €82m, GenSight Biologics is a small cap stock, so it might not be well known by many institutional investors.
Simply Wall St - – Full articleGenSight Biologics SA (EPA:SIGHT): When Will It Breakeven?
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye, and central nervous system. … The €71.97m market-cap company announced a latest loss of -€24.11m on 31 December 2017 for its most recent financial year result. … In this article, I will touch on the expectations for SIGHT’s growth and when analysts expect the company to become profitable
Simply Wall St - – Full articleWhy You Should Be Bearish On GenSight Biologics SA. (EPA:SIGHT)
It's crucial to understand if a company has a strong future based on its current operations and financial status. … SIGHT has high near term liquidity, with short term assets (cash and other liquid assets) amply covering upcoming one-year liabilities, as well as long-term commitments. … One reason I do like SIGHT as a business is its low level of fixed assets on its balance sheet (1.21% of total assets).
Simply Wall St - – Full articleGenSight Biologics SA. (EPA:SIGHT): Is Breakeven Near?
I’ve put together a brief outline of industry analyst expectations for SIGHT, its year of breakeven and its implied growth rate. … Check out our latest analysis for GenSight Biologics SIGHT is bordering on breakeven, according to analysts. … This means that a high growth rate is not unusual, especially if the company is currently in an investment period.
Simply Wall St - – Full articleSIGHT Company Info
Description
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye, and central nervous system. The company develops its products through gene therapy-based approach with technology platforms of mitochondrial targeting sequence and optogenetics. Its lead product candidates include GS010, an AAV2 containing the human wild-type ND4 gene, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy associated with mutation in the ND4 gene; and GS030 that comprises a gene encoding photoactivatable channelrhodopsin for the treatment of reinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. The company also develops products that are preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was founded in 2012 and is headquartered in Paris, France.
Details
| Name: | GenSight Biologics S.A. |
| SIGHT | |
| Exchange: | ENXTPA |
| Founded: | 2012 |
| €43,428,156 | |
| 28,646,541 | |
| Website: | http://www.gensight-biologics.com |
| Address: |
GenSight Biologics S.A. 74, rue du Faubourg Saint-Antoine, Paris, Ile-de-France, 75012, France |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| ENXTPA | SIGHT | Ordinary Shares | Euronext Paris | FR | EUR | 13. Jul 2016 | |
| OTCPK | GSGT.F | Ordinary Shares | Pink Sheets LLC | US | USD | 13. Jul 2016 | |
| DB | G49N | Ordinary Shares | Deutsche Boerse AG | DE | EUR | 13. Jul 2016 | |
| LSE | 0RIM | Ordinary Shares | London Stock Exchange | GB | EUR | 13. Jul 2016 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/23 00:51 |
| End of day share price update: | 2019/05/22 00:00 |
| Last estimates confirmation: | 2019/05/16 |
| Last earnings filing: | 2019/04/29 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
